Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Sponsor
Johns Hopkins University (Other)
Overall Status
Terminated
CT.gov ID
NCT01875770
Collaborator
(none)
47
1
98
0.5
Study Details
Study Description
Brief Summary
This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes
Study Design
Study Type:
Observational
Actual Enrollment
:
47 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)
Actual Study Start Date
:
Jan 1, 2013
Actual Primary Completion Date
:
Oct 11, 2018
Actual Study Completion Date
:
Mar 3, 2021
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Treated with Ranibizumab in previous trial Treated with Ranibizumab in previous trial |
Outcome Measures
Primary Outcome Measures
- Mean change from baseline in BCVA at 5 and 10 years. [10 years]
Mean change from baseline in BCVA at 5 and 10 years.
Secondary Outcome Measures
- Mean change from baseline in foveal thickness at 5 and 10 years [10 years]
Mean change from baseline in foveal thickness at 5 and 10 years
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- All patients who have been enrolled in the following three trials will be included in the study:
- "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)"
Exclusion Criteria:
- None
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Wilmer Eye Institute | Baltimore | Maryland | United States | 21287 |
Sponsors and Collaborators
- Johns Hopkins University
Investigators
- Principal Investigator: Peter Campochiaro, MD, Johns Hopkins University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT01875770
Other Study ID Numbers:
- NA_00079952
First Posted:
Jun 12, 2013
Last Update Posted:
Oct 12, 2021
Last Verified:
May 1, 2021
Keywords provided by Johns Hopkins University
Additional relevant MeSH terms: